Oncolytics Biotech (NASDAQ:ONCY) announces a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for a pivotal Phase 3 study. The trial evaluates pelareorep combined with frontline gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Stock Surge and FDA Milestone
Following the announcement, ONCY shares climb 11% during trading. The agreement stems from a productive Type C meeting with the FDA. Officials confirm the randomized controlled trial design supports pathways to both accelerated and full approval in a single study.
Positive data from a single-arm study bolster confidence, yet the company prioritizes a rigorous randomized approach based on FDA guidance regarding evidentiary standards.
CEO Highlights Patient Impact
Oncolytics Biotech CEO Kelly states, “Every clearly defined treatment prioritizing quality of life for patients enables pelareorep’s essential role. We look forward to soon presenting this to the FDA.”
Pancreatic Cancer Treatment Landscape
Metastatic PDAC impacts about 10,000 new patients annually in the U.S. Gemcitabine plus nab-paclitaxel serves as the current FDA-approved frontline therapy. No approved options exist for patients progressing after initial chemotherapy and checkpoint inhibitors.
Promising Clinical Results
Recent research combining pelareorep with a checkpoint inhibitor shows a median duration of response of 15.5 months, surpassing the standard 9.5 months. Twelve-month survival reaches 82%, compared to 45.7% for standard care.
The FDA’s feedback shapes the finalized protocol, streamlining development for both approval types through this definitive randomized trial.
About Pelareorep
Pelareorep, an intravenously delivered immunotherapeutic oncolytic virus, reactivates anti-tumor immune responses by exposing tumor antigens. Investors welcome this progress in oncology innovation.
